The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
Executive Summary
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
You may also be interested in...
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
CMS Building Rx Price Negotiating Staff Internally; Contracting With Outside Groups ‘Not On Radar’
CMS head Brooks-LaSure says agency is making progress in staffing the drug pricing control programs established by the Inflation Reduction Act. Medicare Center deputy director Cheri Rice will be its acting director under just-unveiled management structure.
As COVID Vaccine Market Goes Private, US Government Can Still Help Firms Boost Sales
Pfizer and Moderna’s ‘endemic’ COVID vaccine market scenarios anticipate much higher booster rates than have been achieved so far, but performance for 2023 may be aided by the Biden Administration campaign to increase shots this winter.